Preparation, characterization and in vitro intestinal absorption of a dry emulsion formulation containing atorvastatin calcium Redispersible dry emulsion of atorvastatin calcium

Drug Delivery

Volumn 16, Issue 1, 2009, Pages 30-36

  Yin, Yong Mei ^a,c   Cui, Fu De ^a   Kim, Jung Sun ^b   Choi, Min Koo ^c   Choi, Byung Chul ^d   Chung, Suk Jae ^c   Shim, Chang Koo ^c   Kim, Dae Duk ^c  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Dongseo University   (South Korea)

^c Seoul National University   (South Korea)

^d Chung Ang University   (South Korea)

Author keywords

Absorption; Dissolution;

Indexed keywords

ATORVASTATIN; DEXTRIN; POLOXAMER; SURFACTANT; DRUG CARRIER; DRUG DERIVATIVE; GLYCEROL; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OLEIC ACID; PYRROLE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; EMULSION; GASTROINTESTINAL ABSORPTION; IN VITRO STUDY; INTESTINE MUCOSA PERMEABILITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAY DRYING; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; HUMAN; INTESTINE ABSORPTION; METHODOLOGY; ORAL DRUG ADMINISTRATION; SOLUBILITY; SPRAGUE DAWLEY RAT; TIME;

ADMINISTRATION, ORAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DEXTRINS; DRUG CARRIERS; EMULSIONS; GLYCEROL; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTESTINAL ABSORPTION; MALE; OLEIC ACIDS; POLOXAMER; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SURFACE-ACTIVE AGENTS; TIME FACTORS;

EID: 70349582119     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717540802481380     Document Type: Article

References (32)

1. Ahmed IS, Aboul-Einien MH (2007). In vitro and in vivo evaluation of a fast-disintegrating lyophilized dry emulsion tablet containing griseofuvin. Eur. J. Pharm. Sci. 32, 58-68.
2. Amidon GL Lennernas H Shah VP, Crison JR (1995). A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420.
3. Ballantyne CM, Herd JA, Ferlic LL, Dunn JK, Farmer JA, Jones PH, Schein JR, GottoJr. AM (1999). Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 99, 736-743.
4. Bhargava S, Agrawal GP (2008). Preparation & characterization of solid inclusion complex of cefpodoxime proxetil with beta-cyclodextrin. Curr. Drug Deliv. 5, 1-6.
5. Corveleyn S, Remon JP (1998a). Formulation of a lyophilized dry emulsion tablet for the delivery of poorly soluble drugs. Int. J. Pharm. 166, 65-74.
6. Corveleyn S, Remon JP (1998b). Bioavailability of hydrochlorothiazide: Conventional versus freeze-dried tablets. Int. J. Pharm. 173, 149-155.
7. Corveleyn S, Remon JP (1999). Stability of freeze-dried tablets at different relative humidities. Drug Dev. Ind. Pharm. 25, 1005-1013.
8. Elversson J, Millqvist-Fureby A (2006). In situ coating-An approach for particle modification and encapsulation of proteins during spray-drying. Int. J. Pharm. 323, 52-63.
9. Floyd AG (1999). Top ten considerations in the development of parenteral emulsions. Pharm. Sci. Technol. To. 2, 134-143.
10. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs Jr. DR, Bangdiwala S, Tyroler HA (1989). Highdensity lipoprowith lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79, 8-15.
11. Grove M Müllertz A, Nielsen JL, Pedersen GP (2006). Bioavailability of seocalcitol II: Development and characterization of self-microemulsifying drug delivery system (SMEDDS) for oral administration containing medium and long chain triglycerides. Eur. J. Pharm. Sci. 28, 233-242.
12. Heinzelmann K, Franke K (1999). Using freezing and drying techniques of emulsions for the microencapsulation of fish oil to improve oxidation stability. Colloids Surf. B 12, 223-229.
13. Itoh K, Matsui S (2002). Improvement of physicochemical properties of N-4472 Part II: Characterization of N-4472 microemulsion and the enhanced oral absorption. Int. J. Pharm. 246, 75-83.
14. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernas H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL (2004). Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol. Pharm. 1, 85-96.
15. Kearney AS, Crawford LF, Mehta SC, Radebaugh GW (1993). The interconversion kinetics, equilibrium, and solubilities of the lactone and hydrocyacid forms of the HMG-CoA reductase inhibitor. CI-981. Pharm. Res. 10, 1461-1465.
16. Molina C, Cadorniga R (1995). Physical stability of lyophilized and sterilized emulsions. (S.T.P.) Pharma Pratiques 5, 63-72.
17. Nakamoto Y, Hashida M, Muranishi S, Sezaki H (1975). Studies on pharmaceutical modification of anticancer agents. Enhanced delivery of bleomycin into lymph by emulsions and drying emulsions. Chem. Pharm. Bull. 23, 3125-3131.
18. Okonogi S, Oguchi T, Yonemochi E, Puttipipatkhachorn S, Yamamoto K (1997). Improved dissolution of ofloxacin via solid dispersion, Int. J. Pharm. 156, 175-180.
19. Pedersen GP, Fäldt P, Bergenståhl B, Kristensen HG (1998a). Solid state characterisation of a dry emulsion: A potential drug delivery system. Int. J. Pharm. 171, 257-270.
20. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyörälä K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ (1998b). Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97, 1453-1460. (Pubitemid 28191300)
21. Porter CJH, Charman SA, Williams RD, Bakalova MV, Charman WN (1996). Evaluation of emulsifiable glasses for the oral administration of cyclosporin in beagle dogs. Int. J. Pharm. 141, 227-237.
22. Shen H, Zhong M (2006). Preparation and evaluation of self-microemulsifying drug delivery system (SMEDDS) containing atorvastatin. J. Pharm. Pharmacol. 58, 1183-1191.
23. Shively ML (1993a). Characterization of oil-in-water emulsions prepared from solid-state emulsions: Effect of matrix and oil phase. Pharm. Res. 10, 1153-1156.
24. Shively ML (1993b). Droplet size distribution within oil-inwater emulsions prepared from solid state dispersions. J. Colloid Interface Sci. 155, 66-69.
25. Shively ML, Dec SF (1994). Solid-state emulsions: Evaluation by 1H and 13C solid-state nuclear magnetic resonance. Pharm. Res. 11, 1301-1305.
26. Shively ML, Thompson DC (1995). Oral bioavailability of vancomycin solid-state emulsions. Int. J. Pharm. 117, 119-122.
27. Takeuchi H, Sasaki H, Niwa T, Hino T, Kawashima Y, Uesugi K, Ozawa H (1992a). Design of redispersible dry emulsion as an advanced dosage form of oily drug (vitamin E nicotinate) by spray-drying technique. Drug Dev. Ind. Pharm. 18, 919-937.
28. Takeuchi H, Sasaki H, Niwa T, Hino T, Kawashima Y, Uesugi K, Ozawa H (1992b). Improvement of photostability of ubidecarenone in the formulation of a novel powdered dosage form termed redispersible dry emulsion. Int. J. Pharm. 86, 25-33.
29. Tarr BD, Yalkowsky SH (1989). Enhancement intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharm. Res. 6, 40-43.
30. Welin-Berger K, Bergenståhl B (2000). Inhibition of Ostwald ripening in local anesthetic emulsions by using hydrophobic excipients in the disperse phase. Int. J. Pharm. 200, 249-260.
31. Witztum, J. L. 1996. Drugs used in the treatment of hyperlipoproteinemias. In: The pharmacological Basis of Therapeutics, 9th ed, eds Ruddon JG, Limbird LE, Molinoff PB, Ruddon RW, 875-897. New York, McGraw-Hill.
32. Wu CY, Benet LZ (2005). Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22, 11-23.